Introduction
The age speci®c incidence rate of breast cancer in women rises until menopause, levels o and then rises again at a much lower rate indicating a possible hormonal in¯uence over the disease risk (Thomas et al., 1997) . The role of estrogen in the etiology of human breast cancer is further supported by risk factors such as early age at menarche and late menopause, high serum or urine estrogen levels in breast cancer patients as well as low levels of sex hormone binding protein leading to high bioavailability of unbound estradiol (Hankinson et al., 1998) . Approximately 50% of all breast cancers are sensitive to hormone treatment indicating a basic role for estrogen in the progression of the disease, as well. In postmenopausal women, local aromatization of androgens to estrogens is the main source of estradiol in the tumor and surrounding tissue (Pike et al., 1993; Simpson et al., 1994) . These local conversions of estrogens as well as the rate-limiting step of conversion of androstenedione to estrone are catalyzed by the aromatase cytochrome P450 complex (Means et al., 1989; Burak et al., 1997) . Clinical ®ndings in patients with aromatase de®ciency as well as in a knockout mouse (ArKo) lacking functional aromatase, illustrate the role of this enzyme for the development of reproductive organs and mammary glands in female and for the regulation of gonadotropins in both male and female (Harada et al., 1992; Fisher et al., 1998) . The gene (CYP19) is regulated in a dierent manner in dierent tissues with hormonally controlled promoters like the gonadal type promoter or adipose stroma cell type promoter (Mahendroo et al., 1993; Harada et al., 1993) . The markedly increased aromatase expression in transformed neoplastic cells may be partly a consequence of using dierent tissue speci®c hormonally regulated promoters. Genetic polymorphisms of CYP19 may be involved in other mechanisms, such as mRNA stabilization, enhancing of transcription or posttranslational regulation of expression. Previously, we reported a polymorphic allele of CYP19 (repeat (TTTA) 12 ) to be signi®cantly more frequent in breast cancer patients than in controls (Kristensen et al., 1998a) . Sourdaine et al. (1994) described several mutations in exons 3, 7 and 10 of the aromatase gene in tumors from breast cancer patients. Since the mutation in exon 10 is in the 3' untranslated region of the mRNA with putative impact on the mRNA stability or regulation of termination of translation, we designed experiments to verify whether it has in¯uence on RNA levels of aromatase and relevant clinical parameters.
Results
A sequence variant caused by a point mutation in exon 10, the 3' untranslated region of CYP19, previously described in tumor tissue (Sourdaine et al., 1994) , was analysed using leukocyte DNA from 399 individuals (163 breast cancer patients and 236 controls) and was shown to be a germline polymorphism. Both the breast cancer patients and the control group population were in Hardy-Weinberg equilibrium with respect to the polymorphism. In addition, genotyping was performed on tumor DNA from 318 breast cancer patients, of which a subset of 156 had been analysed for CYP19 mRNA expression in the tumors. No dierence in heterozygosity at the aromatase locus (15q) was observed between patients genotyped on leukocyte DNA and those genotyped on tumor DNA corrected for stage. Nonetheless, despite the infrequent LOH on chromosome 15 in breast cancer, to evaluate a possible bias caused by LOH in the tumor we have genotyped both blood and tumor DNA from 24 patients all heterozygous for the polymorphism without detecting any LOH.
A higher proportion of the breast cancer patients were carriers of the T allele compared to the control group (55.3 vs 46.6%) (P=0.002). There were signi®cantly more breast cancer patients with TT genotype than controls (31.2 vs 22.5%) (P=0.007) ( Table 1) . A list of odds ratios for the dierent genotypes in the breast cancer and the control group as well as in the dierent groups according to stage of disease are given in Table 2 . The odds ratio of developing breast cancer for TT carriers vs CC+CT carriers is 1.51 (95% CI, 1.04 ± 2.16). When various clinical and histopathological parameters were analysed, patients presenting with stage III and IV disease had signi®cantly more frequent TT genotypes compared to controls (P=0.004) (Table 1), OR 2.09 (95% CI, 1.29 ± 3.36) ( Table 2) .
In order to separate tumors expressing factors for rapid local growth from tumors with metastatic phenotype, we focused on those subjects whose stage of disease was considered high due to large tumor size. The observed dierence in the allele distribution of CYP19 became even higher when patients with high stage of the disease due to large tumor size alone and no distant metastases were only included (P=0.002), OR 3.12 (95% CI, 1.80 ± 5.30). When tumor size was analysed in relation to genotypes, patients with tumors larger than 5 cm were found to be signi®cantly more often TT carriers than control individuals (P=0.001) ( Table 1) . A signi®cant dierence between the genotypes of patients with tumors larger than 5 cm vs patients with smaller tumors was also observed (P=0.045).
The previously described rare A1 allele containing the longest repeat (TTTA) 12 , has been found to be signi®cantly more frequent in breast cancer patients than in controls (3.6 vs 1.6%), indicating that carriers may have an increased risk of developing breast cancer, OR 2.42 (95% CI, 1.03 ± 5.80) (Kristensen et al., 1998a) . Using a subset of the same samples of patients (leukocyte DNA from patient case-series 1, see Materials and methods) we could demonstrate that this polymorphism is in strong linkage disequilibrium with the more frequent polymorphism in exon 10 described here (P50.0001) ( Table 3) .
In order to explore the possible dierence in expression of a C and T allele of CYP19 we analysed the mRNA levels and the alternative switch of promoter in the tumors of 156 of the genotyped patients. Alternative use of promoters, followed by alternative splicing of a dierent untranslated exon 1 and providing a tissue speci®c regulation of gene expression of CYP19 has been repeatedly reported. In healthy adipose tissues, the most often used promoter results in the expression of exon 1.4 (Mahendroo et al., 1993) also abbreviated as 1b (Harada et al., 1993) . In tumor tissues, however, a switch to ovary speci®c exon 1, abbreviated as 1c (Harada et al., 1993) or exon II (Mahendroo et al., 1993) has been observed to be signi®cantly more frequent than in healthy tissue (Harada et al., 1995) . In 99 of the tumor samples studied here, the sole or the predominantly expressed exon 1 was either the adipose tissue speci®c exon 1b or the ovary tissue speci®c exon 1c. In 39 of the tumor samples there was no detectable CYP19 mRNA and in 18 the use of promoter was ambiguous (in ten cases there was equal amount of transcripts containing 1b and 1c, in four cases there was expression from a dierent promoter (1d), and in four cases the detection of promoter failed). These cases were excluded from further analysis. Quantitation of CYP19 mRNA showed a wide range of expression. When comparing the genotypes in patients with levels of CYP19 mRNA (CYP19 mRNA/b-actin, above and below the median level) patients with the TT genotype had signi®cantly more often levels of CYP19 mRNA above the median (P=0.018) ( Table 4) . The presence of TT genotype was also associated with the alternative use of promoter. Transcripts containing the atypical ovary speci®c exon 1 (abbreviated 1c or exon II) were signi®cantly more often found in the tumors of individuals with a TT genotype (P=0.004). This switch of promoters was strongly associated with elevated mRNA as 44/69 (64%) of the tumors where the adipose tissue promoter was used had mRNA levels below median, compared to only 6/30 (20%) of those with ovarian promoter. High levels of mRNA expression (above median) were strongly associated with the expression of the ovary promoter (24/30) (P50.001).
Discussion
The polymorphism in exon 10 may possibly enhance the transcription from the ovary promoter and may thus lead to elevated mRNA levels, or it may contribute to regulation independently, by resulting in dierently stable ovary speci®c or adipose speci®c transcripts. The switch of promoters was strongly associated with elevated mRNA levels and may be responsible for the observed upregulation of transcription of CYP19. Computer modeling (Walter et al., 1994) suggested two dierent folding patterns for the 3' end of the CYP19 transcript, depending on the nucleotide in the polymorphic position, C or T. The C ± T change in this proposed computer model destroys an AT base pair and shortens the aected helix by two base pairs, since the neighboring T-A base pair is destabilized by the mutation. This may lead to weakening or destroying of this motif and may in¯uence mRNA stability. Alternatively, the polymorphism may contribute to dierent responsiveness of the ovary speci®c promoter to cAMP dependent regulation (Zhao et al., 1997; Michael et al., 1997) or the regulation of the adipose speci®c promoter by TNF-a or class I cytokines, such as IL-6 18. However, we could not exclude that the genetic polymorphism in exon 10 of CYP19 described by us may be in linkage disequilibrium with another, unknown genetic variant, which may be the functionally responsible one. Since the polymorphism is in the vicinity of the UAG (19 nucleotides downstream of termination of translation), one may speculate that a possible secondary structure of the transcript might in¯uence both the stability of the transcript and the regulation of translation termination. Toda et al. (1989) described alternative RNA processing using dierent poly(A) signals of aromatase mRNA. It is under current investigation whether the polymorphism in exon 10 described here is associated with these poly(A) variants. Our data indirectly suggest that the T-allele of the CYP19 gene is associated with a`high activity' phenotype, since we observe a strong association of the genotype to mRNA levels and large tumor size. High activity of aromatase has been directly related to mammary tumor cell proliferation (Durgam et al., 1995) . It has been shown that insertion of the proviral MMTV (mouse mammary tumor virus) within exon 10 in the 3' untr of CYP19, leads to overexpression of the gene, resulting in mammary tumor cell proliferation in a gene dosage dependent manner, highly potentiated by androstenedione ± the principal substrate of aromatase, precursor of estradiol (Durgam et al., 1995) . This overexpression may be due to the disruption of a negative regulatory element by integration of the MMTV in the 3' untr of CYP19 (aromatase) (Durgam et al., 1995) of the mouse. Here we describe a polymorphism in the same area of the human CYP19, the distribution of which signi®cantly diers between breast cancer patients and controls. Since the frequency of the polymorphic T allele was particularly high among patients presenting with high stage disease and with tumors larger than 5 cm and was signi®cantly associated with mRNA levels as well as a switch from the normally used adipose promoter to ovary promoter, individuals homozygous for this allele may have accelerated production of tissue estrogen and therefore higher risk for developing tumors with rapid local growth.
Methods
DNA samples from a total of 481 breast cancer patients were genotyped. Genotyping was performed on three dierent case-series: (1) Leukocyte DNA from 163 patients, admitted to the Norwegian Radium Hospital, mean age at diagnosis 57 (27 ± 89), where all tumor stages were observed (stadium I, II, III and Table 3 Association between two polymorphisms in the CYP19 (aromatase) gene, tetranucleotide repeat in intron 4. The repeat length in the dierent alleles were: A1 (TTTA) 12 , A2 (TTTA) 11 , A3 (TTTA) 9 , A4 (TTTA) 8 , A5 (TTTA) 7   CC  CT  TT  Total   A1A2  0  3  6  9  A1A4  0  1  0  1  A1A5  0  8  0  8  A2A2  7  9  30  46  A2A4  2  3  14  19  A2A5  9  75  16  100  A4A4  0  1  2  3  A4A5  2  34  2  38  A5A5  61  23  6  90  Total  81  157  76  314 Association between A1 and T, P50.0001; association between A5 and C, P50.0001 
Genotyping
A modi®ed automated DNA sequencing with ā uorescent labeled primer was used to genotype PCR products in a single sequencing reaction (SSR) (Kristensen et al., 1998b) . Single sequencing reactions analysed on an automated DNA sequencer can be used as a universal tool for screening for all types of known mutations in various genes. Compared to analysis by full sequencing, four times more samples can be analysed per gel in considerably shorter time. In many circumstances one is not interested in complete DNA sequences, but only in dierences between them. In these cases, single sequencing reactions have been used for many years, e.g. to screen recombinant vectors for a given insert and for other purposes. We have shown that single sequencing reactions performed on PCR products, with subsequent analysis on an ALF Express DNA sequencer, can be as informative, sensitive and accurate as complete sequencing reactions for the genotyping of known point mutations in human DNA (Kristensen et al., 1998b) . This is achieved by using the mutated Taq polymerase (Thermosequence (Amersham-Pharmacia) or AmpliTaqFS (Perkin Elmer)), in cycle sequencing reactions with one single dideoxyanalog, chosen to correspond to the base found in one of the two alleles. In the example shown in Figure 1 there is either a C or a T in the polymorphic position in the DNA. In a T-track sequencing reaction a T/T individual will have a normally sized T in this position (contribution to the signal from both alleles), whereas a person with a C/T genotype will have a T with half the normal size (contribution from only one allele) and a C/C individual will have no signal in that position in the T-track. Analysing the mutation in exon 10 of the human aromatase gene we have shown that an unambiguous genotype could be elucidated in more than 90% of the analysed samples (Kristensen et al., 1998b) . This simpli®ed sequencing-based genotyping method makes it possible to analyse a high number of samples per sequencing gel, without loss of sensitivity and accuracy. A 367 bp long fragment of the gene (CYP19) was ampli®ed from leukocyte DNA using primers as described previously (Sourdaine et al., 1994) . The polymorphic site to be investigated was situated 75 nucleotides from the 5' end of the Figure 1 Single T-tracks using the AlleleLinks package (Pharmacia Biotech). The polymorphic site is in position 75. Single track analysis consisted of ®rst identifying peaks, followed by sizing the products using two of the invariant sites (marked with ®lled dots) as internal standards, and then measuring the relative area under the relevant peaks by setting the area under one of the invariant neighboring T-peaks to 1. The peak table was then exported to a text ®le and imported into Microsoft Excel for further analysis. TT homozygous genotype is presented in lanes 27, 29, 31 ± 34, 36, heterozygous CT genotype in lane 30, homozygous CC is presented in lanes 28 and 35. An ambiguous result was obtained in lane 26, subsequently genotyped as CC sequencing primer. After data collection single T-tracks were analysed using the AlleleLinks package (both from Pharmacia Biotech) ( Figure 1 ). The peak table was then exported to a text ®le and imported into Microsoft Excel for further analysis.
Quantitation and analysis of alternative usage of exons 1 of aromatase mRNA RNA was prepared from fresh frozen tissues as described previously (Harada et al., 1993) . Quantitative analysis of aromatase mRNA was performed by competitive reverse transcription ± PCR, using human aromatase cDNA as an internal standard as described previously (Harada et al., 1993 (Harada et al., , 1995 . A CYP19 speci®c sense¯uorescence labeled primer and internal standard speci®c antisense primer were used and thē uorescent PCR products were electrophoresed in a 2% agarose gel and analysed with a Gene Skanner 362 Fluorescence Fragment Analyzer (ABI Perkin Elmer). The amount of aromatase mRNA was calculated from the peak areas of the¯uorescent products by the internal standard method and corrected after quantita-tion of b-actin mRNA. The utilization of alternative exons 1 of the aromatase gene was investigated by RT ± PCR using sense primers speci®c for exons 1a, 1b, 1c, 1d and a¯uorescent labeled antisense primer, speci®c for exon 2 according to the previously described protocol (Harada et al., 1993) .
Statistical analysis
Statistical evaluation was performed using the Pearson Chi square test with Yates' correction. P values less than 0.05 were considered statistically signi®cant. Odds ratios with 95% con®dence intervals were calculated where appropriate by standard method for retrospective case control studies.
